Literature DB >> 23179578

Pharmacodynamic models for discrete data.

Ines Paule1, Pascal Girard, Gilles Freyer, Michel Tod.   

Abstract

Clinical outcomes are often described as events: death, stroke, epileptic seizure, multiple sclerosis lesions, recurrence of cancer, disease progression, pain, infection and bacterial/viral eradication, severe toxic adverse effect, resistance to treatment, etc. They may be quantified as time-to-event, counts of events per time interval (rates), their severity grade, or a combination of these. Such data are discrete and require specific modelling structures and methods. This article references the most common modelling approaches for categorical, count and time-to-event data, and reviews examples of such models applied in the analysis of pharmacodynamic data. Modelling is useful for identification of influential factors related to the clinical outcome, characterization and quantification of their impact, for making better informed predictions and clinical decisions, assessments of efficacy of therapeutic interventions, optimizing the individual treatments and drug development studies.

Entities:  

Mesh:

Year:  2012        PMID: 23179578     DOI: 10.1007/s40262-012-0014-9

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  57 in total

1.  Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data.

Authors:  Gordon Graham; Suneel Gupta; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

2.  Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.

Authors:  Catherijne A J Knibbe; Klaas P Zuideveld; Joost DeJongh; Paul F M Kuks; Leon P H J Aarts; Meindert Danhof
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

3.  A mixed-effects regression model for three-level ordinal response data.

Authors:  Rema Raman; Donald Hedeker
Journal:  Stat Med       Date:  2005-11-15       Impact factor: 2.373

4.  Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain.

Authors:  K G Kowalski; S Olson; A E Remmers; M M Hutmacher
Journal:  Clin Pharmacol Ther       Date:  2007-09-19       Impact factor: 6.875

5.  Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data.

Authors:  Inès Paule; Pascal Girard; Michel Tod
Journal:  Comput Methods Programs Biomed       Date:  2011-05-26       Impact factor: 5.428

6.  Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.

Authors:  A Forrest; S Chodosh; M A Amantea; D A Collins; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

7.  Multi-state models for the analysis of time-to-event data.

Authors:  Luís Meira-Machado; Jacobo de Uña-Alvarez; Carmen Cadarso-Suárez; Per K Andersen
Journal:  Stat Methods Med Res       Date:  2008-06-18       Impact factor: 3.021

Review 8.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authors:  Brett E Houk; Carlo L Bello; Bill Poland; Lee S Rosen; George D Demetri; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-05       Impact factor: 3.333

9.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

10.  Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients.

Authors:  Matthew M Hutmacher; Sriram Krishnaswami; Kenneth G Kowalski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-12-06       Impact factor: 2.745

View more
  3 in total

1.  Modeling and simulation of count data.

Authors:  E L Plan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-08-13

2.  PharmML in Action: an Interoperable Language for Modeling and Simulation.

Authors:  R Bizzotto; E Comets; G Smith; F Yvon; N R Kristensen; M J Swat
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-09-15

Review 3.  A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.

Authors:  Dan Lu; Tong Lu; Mark Stroh; Richard A Graham; Priya Agarwal; Luna Musib; Chi-Chung Li; Bert L Lum; Amita Joshi
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-25       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.